Drug intelligence / Profile preview

mAb4

Development stage: Preclinical
Lead developer: Suzhou Stainwei Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

**mAb4** is a preclinical monoclonal-antibody candidate from Suzhou Stainwei Biotechnology for inflammatory diseases. The company pipeline identifies CD118, also known as the leukemia inhibitory factor receptor, as its intended target. Publicly available pipeline information does not disclose the antibody sequence, isotype, epitope, functional activity, formulation, route of administration, or specific inflammatory indication.

Other names: monoclonal antibody 4

Targets

LIFR (Leukemia inhibitory factor receptor)

Beyond the preview

Go deeper on mAb4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb4.

Explore the full profile